MiNK Therapeutics (NASDAQ:INKT) Director Sells $19,140.00 in Stock
by Michael Walen · The Markets DailyMiNK Therapeutics, Inc. (NASDAQ:INKT – Get Free Report) Director Barbara Ryan sold 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $12.76, for a total value of $19,140.00. Following the transaction, the director owned 21,969 shares of the company’s stock, valued at $280,324.44. This represents a 6.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Barbara Ryan also recently made the following trade(s):
- On Tuesday, March 10th, Barbara Ryan sold 1,300 shares of MiNK Therapeutics stock. The shares were sold at an average price of $15.40, for a total value of $20,020.00.
- On Monday, March 9th, Barbara Ryan sold 200 shares of MiNK Therapeutics stock. The shares were sold at an average price of $10.17, for a total value of $2,034.00.
MiNK Therapeutics Stock Down 6.9%
NASDAQ INKT traded down $0.88 during trading on Friday, hitting $11.87. 51,453 shares of the stock traded hands, compared to its average volume of 187,181. The company has a market capitalization of $59.11 million, a P/E ratio of -4.18 and a beta of 0.47. The firm has a 50-day simple moving average of $11.35 and a 200-day simple moving average of $11.37. MiNK Therapeutics, Inc. has a 12-month low of $6.80 and a 12-month high of $76.00.
MiNK Therapeutics (NASDAQ:INKT – Get Free Report) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.20. As a group, research analysts predict that MiNK Therapeutics, Inc. will post -2.75 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities analysts have recently commented on INKT shares. HC Wainwright reiterated a “buy” rating and issued a $35.00 target price on shares of MiNK Therapeutics in a report on Monday, May 18th. Wall Street Zen upgraded MiNK Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Weiss Ratings upgraded MiNK Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 27th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, MiNK Therapeutics currently has an average rating of “Hold” and a consensus target price of $35.00.
Get Our Latest Stock Analysis on INKT
Institutional Inflows and Outflows
An institutional investor recently raised its position in MiNK Therapeutics stock. Geode Capital Management LLC boosted its stake in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT – Free Report) by 11.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,247 shares of the company’s stock after buying an additional 1,441 shares during the quarter. Geode Capital Management LLC owned approximately 0.30% of MiNK Therapeutics worth $159,000 as of its most recent SEC filing. Institutional investors own 2.87% of the company’s stock.
About MiNK Therapeutics
MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.
MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.